Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

481. Cost-effectiveness of current and optimal treatment for schizophrenia

Cost-effectiveness of current and optimal treatment for schizophrenia Cost-effectiveness of current and optimal treatment for schizophrenia Cost-effectiveness of current and optimal treatment for schizophrenia Andrews G, Sanderson K, Corry J, Issakidis C, Lapsley H Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical (...) assessment on the reliability of the study and the conclusions drawn. Health technology This study compared services currently provided (current treatment (CT)) for schizophrenia with those that could be achieved with wider implementation of evidence based interventions (referred to as optimal treatment (OT)). CT was defined according to local epidemiological and practice pattern data, and OT was defined by recommendations in the clinical practice guideline literature, primarily the PORT study

2003 NHS Economic Evaluation Database.

482. A systematic review of atypical antipsychotic drugs in schizophrenia

A systematic review of atypical antipsychotic drugs in schizophrenia A systematic review of atypical antipsychotic drugs in schizophrenia A systematic review of atypical antipsychotic drugs in schizophrenia Bagnall AM, Jones L, Ginnelly L, Lewis R, Glanville J, Gilbody S, Davies L, Torgerson D, Kleijnen J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation Bagnall AM, Jones L, Ginnelly L, Lewis R, Glanville J, Gilbody S, Davies L, Torgerson D, Kleijnen J. A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technology Assessment 2003; 7(13): 1-204 Authors' objectives The clinical effectiveness, safety and cost-effectiveness of atypical antipsychotic drugs in schizophrenia were compared with conventional antipsychotic drugs, placebo and other atypical antipsychotic drugs. As secondary objectives, the response

2003 Health Technology Assessment (HTA) Database.

483. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. Full Text available with Trip Pro

Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. Although olanzapine has been widely adopted as a treatment of choice for schizophrenia, its long-term effectiveness and costs have not been evaluated in a controlled trial in comparison with a standard antipsychotic drug.To evaluate the effectiveness and cost impact of olanzapine compared with haloperidol in the treatment of schizophrenia.Double-blind, randomized controlled (...) trial with randomization conducted between June 1998 and June 2000 at 17 US Department of Veterans Affairs medical centers.Three hundred nine patients with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition diagnosis of schizophrenia or schizoaffective disorder, serious symptoms, and serious dysfunction for the previous 2 years. Fifty-nine percent fully completed and 36% partially completed follow-up assessments.Patients were randomly assigned to receive flexibly dosed

2003 JAMA Controlled trial quality: predicted high

484. Schizophrenia and weight management: a systematic review of interventions to control weight

Schizophrenia and weight management: a systematic review of interventions to control weight Schizophrenia and weight management: a systematic review of interventions to control weight Schizophrenia and weight management: a systematic review of interventions to control weight Faulkner G, Soundy A A, Lloyd K CRD summary This review assessed interventions to control weight gain in patients with schizophrenia. The authors concluded that dietary and exercise counselling as part of a behavioural (...) modification programme can control weight, but that widespread use of pharmacological interventions cannot be recommended. However, the behavioural intervention studies were of a poor quality, thus the evidence for implementation is weak. Authors' objectives To assess the effects of interventions to control weight gain in patients with schizophrenia. Searching The following databases were searched for studies published in English: PsycINFO (1872 to October 2002); the Cochrane Schizophrenia Group's Register

2003 DARE.

485. Vocational rehabilitation in schizophrenia and other psychotic disorders: a literature review and meta-analysis of randomized controlled trials

Vocational rehabilitation in schizophrenia and other psychotic disorders: a literature review and meta-analysis of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2003 DARE.

486. Clozapine v. conventional antipsychotic drugs for treatment-resistant schizophrenia: a re-examination

Clozapine v. conventional antipsychotic drugs for treatment-resistant schizophrenia: a re-examination Clozapine v. conventional antipsychotic drugs for treatment-resistant schizophrenia: a re-examination Clozapine v. conventional antipsychotic drugs for treatment-resistant schizophrenia: a re-examination Moncrieff J CRD summary This poorly reported review compared clozapine with conventional anti-psychotics for treatment-resistant schizophrenia. The author concluded that clozapine was not shown (...) to be consistently and definitively better than conventional anti-psychotics. The review has several methodological weaknesses and its unclear whether the quality of the included studies and the synthesis of them, can be relied upon. Authors' objectives To compare clozapine with conventional antipsychotics for treatment-resistant schizophrenia, and to investigate potential sources of differences in effect between studies. Searching Trials were identified from a previous Cochrane review (see Other Publications

2003 DARE.

487. Cognitive rehabilitation in schizophrenia: a quantitative analysis of controlled studies

Cognitive rehabilitation in schizophrenia: a quantitative analysis of controlled studies Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2003 DARE.

488. A review of cognitive training in schizophrenia

A review of cognitive training in schizophrenia A review of cognitive training in schizophrenia A review of cognitive training in schizophrenia Twamley E W, Jeste D V, Bellack A S CRD summary This review assessed the effectiveness of cognitive training (CT) interventions for people with schizophrenia. The authors concluded that there was evidence that CT can yield some positive effects in terms of cognitive performance, psychiatric symptoms and everyday functioning. The authors' conclusions (...) appear justified, although it is difficult to assess their reliability given the limitations in the review methods and reporting. Authors' objectives To assess the effectiveness of cognitive training (CT) interventions that aim to improve neuropsychological functioning in people with schizophrenia. Searching MEDLINE and PsycINFO were searched from inception to 2001 for peer-reviewed reports in the English language. The authors also checked the reference lists of identified articles for additional

2003 DARE.

489. A systematic review of atypical antipsychotic drugs in schizophrenia

A systematic review of atypical antipsychotic drugs in schizophrenia A systematic review of atypical antipsychotic drugs in schizophrenia A systematic review of atypical antipsychotic drugs in schizophrenia Bagnall A M, Jones L, Ginnelly L, Lewis R, Glanville J, Gilbody S, Davies L, Torgerson D, Kleijnen J CRD summary This review assessed the safety and cost-effectiveness of 'atypical' antipsychotic drugs in patients with schizophrenia. The authors concluded that the evidence was limited (...) and should be treated with caution. Generally, none of the eight drugs of interest were found to be more effective than the others, with one exception. The authors' cautious conclusions are likely to be reliable. Authors' objectives The main objectives were to assess the clinical effectiveness, safety and cost-effectiveness of 'atypical' antipsychotic drugs in schizophrenia in comparison with conventional antipsychotic drugs, placebo and other atypical antipsychotic drugs. The secondary objectives

2003 DARE.

490. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial

Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2003 NHS Economic Evaluation Database.

491. Cognitive-behavioural therapy and motivational intervention for schizophrenia and substance misuse - 18-month outcomes of a randomised controlled trial

: Wiley; 2002. p. 265-80. Indexing Status Subject indexing assigned by NLM MeSH Caregivers /psychology; Cognitive Therapy /methods; Costs and Cost Analysis /methods; Diagnosis, Dual (Psychiatry); Female; Humans; Male; Mental Health Services /economics; Middle Aged; Motivation; Psychiatric Status Rating Scales; Recurrence; Schizophrenia /therapy; Schizophrenic Psychology; Substance-Related Disorders /psychology /therapy; Treatment Outcome AccessionNumber 22003001507 Date bibliographic record published (...) Cognitive-behavioural therapy and motivational intervention for schizophrenia and substance misuse - 18-month outcomes of a randomised controlled trial Cognitive-behavioural therapy and motivational intervention for schizophrenia and substance misuse - 18-month outcomes of a randomised controlled trial Cognitive-behavioural therapy and motivational intervention for schizophrenia and substance misuse - 18-month outcomes of a randomised controlled trial Haddock G, Barrowclough C, Tarrier N

2003 NHS Economic Evaluation Database.

492. Cost-effectiveness of amisulpride compared with risperidone in patients with schizophrenia

Cost-effectiveness of amisulpride compared with risperidone in patients with schizophrenia Cost-effectiveness of amisulpride compared with risperidone in patients with schizophrenia Cost-effectiveness of amisulpride compared with risperidone in patients with schizophrenia Nicholls C J, Hale A S, Freemantle N Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Atypical antipsychotic treatments for patients with schizophrenia were studied. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population consisted of patients with schizophrenia. The inclusion criteria specified patients with a diagnosis of paranoid, disorganised, undifferentiated or residual schizophrenia

2003 NHS Economic Evaluation Database.

493. Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK

Resources /economics; Hospitalization /economics; Humans; Life Tables; Models, Statistical; Prevalence; Risk Factors; Schizophrenia /drug therapy /epidemiology; Schizophrenic Psychology; Suicide /economics /prevention & control AccessionNumber 22003008153 Date bibliographic record published 31/10/2003 Date abstract record published 31/10/2003 NHS Economic Evaluation Database (NHS EED) Produced by the Centre for Reviews and Dissemination Copyright © 2019 University of York Homepage Options Print PubMed (...) Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK Duggan A, Warner J, Knapp M, Kerwin R, Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains

2003 NHS Economic Evaluation Database.

494. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. Full Text available with Trip Pro

Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. An association between use of cannabis in adolescence and subsequent risk of schizophrenia was previously reported in a follow up of Swedish conscripts. Arguments were raised that this association may be due to use of drugs other than cannabis and that personality traits may have confounded results. We performed a further analysis of this cohort to address these uncertainties (...) while extending the follow up period to identify additional cases.Historical cohort study.1969-70 survey of Swedish conscripts (>97% of the country's male population aged 18-20).50 087 subjects: data were available on self reported use of cannabis and other drugs, and on several social and psychological characteristics.Admissions to hospital for ICD-8/9 schizophrenia and other psychoses, as determined by record linkage.Cannabis was associated with an increased risk of developing schizophrenia

2002 BMJ

495. Haloperidol decanoate doses of 200, 100, or 50 mg/month reduced symptomatic exacerbations more than a 25 mg/month dose in schizophrenia. (Abstract)

Haloperidol decanoate doses of 200, 100, or 50 mg/month reduced symptomatic exacerbations more than a 25 mg/month dose in schizophrenia. 12440454 2002 11 20 2003 11 03 1362-0347 5 4 2002 Nov Evidence-based mental health Evid Based Ment Health Haloperidol decanoate doses of 200, 100, or 50 mg/month reduced symptomatic exacerbations more than a 25 mg/month dose in schizophrenia. 113 Marois Marie-Josée MJ Centre de recherche Université Laual Robert-Gifford Beauport, Quebec, Canada. Roy Marc-André

2002 Evidence-Based Mental Health Controlled trial quality: uncertain

496. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. Full Text available with Trip Pro

Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. To quantify the association between olanzapine and diabetes.Population based nested case-control study.United Kingdom based General Practice Research Database comprising 3.5 million patients followed between 1987 and 2000.19 637 patients who had been diagnosed as having and treated for schizophrenia. 451 incident cases of diabetes were

2002 BMJ

497. Schizophrenia and velo-cardio-facial syndrome. (Abstract)

Schizophrenia and velo-cardio-facial syndrome. Velo-cardio-facial syndrome (VCFS), the most frequent known interstitial deletion identified in man, is associated with chromosomal microdeletions in the q11 band of chromosome 22. The VCFS phenotype is complex, with multiple congenital abnormalities affecting several tissues and organs, many of which are derived from neural crest cells. Although phenotypic variability occurs, individuals with VCFS have high rates of psychiatric disorder (...) , especially schizophrenia. Additionally, an increased prevalence of chromosome 22q11 deletions has been reported in populations of people with schizophrenia. Furthermore, results of molecular genetic studies suggest that a schizophrenia susceptibility locus maps to chromosome 22q. These data indicate that aside from being the child of two parents with schizophrenia or the monozygotic co-twin of an affected individual, VCFS and deletion 22q11 represents the highest known risk factor for the development

2002 Lancet

498. Perazine for schizophrenia. (Abstract)

Perazine for schizophrenia. Perazine is an old phenothiazine derivative used for the treatment of people with schizophrenia which has a reputed low level of extrapyramidal side-effects. However, its use is restricted in the sense that - to the best knowledge of the reviewers - it is only marketed in Germany, Poland, Yugoslavia and the Netherlands.To examine the effects of perazine for those with schizophrenia, and schizophrenia-like psychoses.Electronic searches of the Cochrane Schizophrenia (...) Group's register which includes relevant randomised controlled trials from the bibliographic databases Biological Abstracts, CINAHL, The Cochrane Library, EMBASE, MEDLINE, PsycLIT, LILACS, PSYNDEX, Sociological Abstracts and Sociofile were undertaken. References of all included studies were searched for further trials. Pharmaceutical companies and authors of trials were contacted.All randomised controlled trials that compared perazine with other treatments for people with schizophrenia

2002 Cochrane

499. Benperidol for schizophrenia. (Abstract)

Benperidol for schizophrenia. Benperidol is a relatively old antipsychotic drug, marketed since 1966, used in Germany for 30 years, but also available in Belgium, Greece, Italy, the Netherlands and the UK. Benperidol is a butyrophenone antipsychotic, with the highest neuroleptic potency in terms of D2 receptor blockade. Those taking it are, therefore, reputed to be at high risk of extrapyramidal side effects, but benperidol's unusual profile may render it of value to subgroups of people (...) with schizophrenia.To examine the clinical effects and safety of benperidol for those with schizophrenia and schizophrenia-like psychoses.The reviewers searched the Cochrane Schizophrenia Group's register (January 2001) which includes relevant randomised controlled trials from the bibliographic databases Biological Abstracts, CINAHL, The Cochrane Library, EMBASE, MEDLINE, PsycLIT, LILACS, PSYNDEX, Sociological Abstracts and Sociofile. We also searched the references of all included studies and contacted

2002 Cochrane

500. Amisulpride for schizophrenia. Full Text available with Trip Pro

Amisulpride for schizophrenia. The treatment of schizophrenia with old, 'typical' antipsychotic drugs such as haloperidol can be problematic, because many people treated with these drugs will suffer from movement disorders. Amisulpride is said to be an "atypical" antipsychotic which induces less movement disorder and which is effective for the negative symptoms of schizophrenia.To evaluate the effects of amisulpride as compared with placebo, typical and atypical antipsychotic drugs (...) for schizophrenia.The authors carried out electronic searches of Biological Abstracts (1982-1999), CINAHL (1982-1999), Cochrane Library (Issue 4, 1999), Cochrane Schizophrenia Group's Register (November 2000), EMBASE (1980-1999), LILACS(1982-1999), MEDLINE (1966-1999) and PsycLIT (1974-1999). They checked all identified studies for further trial citations, and sought these studies in the Science Citation Index. They also contacted authors of trials and the manufacturer of amisulpride.All randomised controlled

2002 Cochrane